{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"LTE60","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"An interim analysis was planned occur after 20 PFS events were observed in either arm (roughly 50% information time). The futility threshold for paclitaxel and carboplatin relative to BEP was HR\\>1.10. Median followup time was 48 months.\n\nThe study closed at the interim analysis for futility, and difficulty with accrual. At the time of closures, 63 of a planned 128 patients had enrolled at the time of accrual suspension."},"pointOfContact":{"email":"purdyc@nrgoncology.org","organization":"NRG Oncology","phone":"(716) 845-1300","phoneExt":"2296","title":"Christopher Purdy on behalf of Austin Miller PhD"}}